SAO PAULO (Reuters) – Brazilian company Precisa Medicamentos, representing India’s Bharat Biotech, on Monday said it requested that the country’s health regulator, Anvisa, grant emergency authorization to use the Covaxin COVID-19 vaccine.
In addition, it said Covaxin would be trialed in a Phase Three study in Brazil carried out in partnership with Sao Paulo’s Albert Einstein hospital.
(Reporting by Marcelo Rochabrun; Editing by Leslie Adler)
